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Abstract: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host-response to 
infections. Osteopontin (OPN) is an extracellular matrix protein involved in the inflammatory 
response. Our aim was to evaluate the diagnostic and prognostic performance in sepsis of a single 
OPN determination in the Emergency Department (ED). We conducted a single-centre prospective 
observational study in an Italian ED where we enrolled 102 consecutive patients presenting with 
suspected infection and qSOFA ≥ 2. OPN plasma concentration was found to be an independent 
predictor of sepsis (OR = 1.020, 95% CI 1.002–1.039, P = 0.031) and the diagnostic receiver operating 
characteristic (ROC) curve resulted in an area under the curve (AUC) of 0.878. OPN levels were 
positively correlated to plasma creatinine (r = 0.401 with p = 0.0001), but this relation was not 
explained by the development of acute kidney injury (AKI), since no difference was found in OPN 
concentration between AKI and non-AKI patients. The analysis of 30-days mortality showed no 
significant difference in OPN levels between alive and dead patients (p = 0.482). In conclusion, a 
single determination of OPN concentration helped to identify patients with sepsis in the ED, but it 
was not able to predict poor prognosis in our cohort of patients. 
Keywords: Osteopontin; biomarkers; sepsis; Emergency Department; diagnosis; risk stratification; 
prognosis 
 
1. Introduction 
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Sepsis is a life-threatening organ dysfunction caused by a dysregulated host-response to 
infection, affecting about 13 million people every year worldwide, with mortality rates higher than 
30% according to some reports [1]. 
Septic shock, on the other hand, identifies a subset of patients in which sepsis is associated with 
both persisting hypotension that requires vasopressors to maintain a mean arterial pressure ≥65 
mmHg and a serum lactate level >2 mmol/L, despite adequate volume resuscitation [1]. The 
identification of organ dysfunction in patients with a suspected infection relies on an acute increase 
of two points in the Sequential Organ Failure Assessment (SOFA) score, which combines clinical and 
laboratory parameters suggestive of different organ impairments [2]. 
Nevertheless, sepsis and septic shock are time-dependent conditions in which a delay in 
antibiotic administration is associated with a significant increase in mortality rates, whereas prompt 
recognition and early treatment initiation are known to improve the patient’s outcome [3]. For these 
reasons, in the Emergency Department (ED) the SOFA score appears to have great limits of 
application, mostly related to the amount of time required to be completed, whilst the use of the 
quick-SOFA score (qSOFA) has been recommended for a rapid identification of septic patients [1]. 
In addition, several biomarkers have been proposed [4,5] to improve the accuracy of qSOFA and 
accelerate the diagnostic pathway as well as the prognostic stratification of septic patients in the ED. 
However, a benchmark is still lacking [6–9]. Among them, Osteopontin (OPN) seems to be a 
promising diagnostic tool, according to the results of previous studies on animal models and 
Intensive Care Unit (ICU) patients. OPN is an extracellular matrix protein involved in the 
inflammatory response: as an integrin-binding protein, it modulates leukocyte activation, migration 
and differentiation as well as cytokine secretion both in acute and chronic inflammation [10–13]. It 
has been shown that OPN circulating levels not only are elevated in sepsis [14], but they also 
progressively increase throughout Systemic Inflammatory Response Syndrome (SIRS), sepsis and 
septic shock [15] and they are associated with higher mortality rates both in animal models [16] and 
septic patients [15,17]. Furthermore, OPN has been demonstrated to be an independent predictor of 
both ICU and long-term mortality in critically ill patients (including septic patients); in particular, the 
prognostic power of OPN levels measured at day three from ICU admission has been found to be 
superior compared to the one of other routine biomarkers of inflammation, infection and organ 
failure such as C-reactive protein (CRP), international normalized ratio (INR) and procalcitonin (PCT) 
[17]. However, to date, little is known about the potential role of OPN as an early diagnostic 
biomarker of sepsis and septic shock, particularly in an ED setting. 
The aim of this study was, thus, to evaluate if a single OPN determination at the first medical 
contact in the ED could be a useful tool for the emergency physician in the diagnostic workup and in 
the risk stratification of patients with sepsis. 
2. Materials and Methods 
2.1. Setting and Patients 
This single-centre, prospective, observational, pilot study was performed in the ED of the 
“Maggiore della Carità” University Hospital in Novara (Italy) from October 2016 to March 2018. 
Patients presenting to the ED with suspected sepsis according to the Sepsis-3 criteria (suspected 
infection and qSOFA ≥2) [1] were consecutively enrolled. Exclusion criteria were pregnancy, age < 18 
years and lack of a signed informed consent. 
The study was conducted according to the guidelines of the local ethical committee in 
conformity to the principles of the Declaration of Helsinki and was prospectively registered at the 
Australian New Zealand Trials Registry (ACTRN12617000429358). 
At the time of the ED visit, clinical data were recorded (including demographic characteristics, 
past medical history, vital signs, physical examination findings, laboratory results and imaging) and 
plasma and urine samples were collected, aliquoted and stored at −80°C. Patients were then clinically 
re-evaluated after 24 and 48 hours and at 7 days or at discharge. A telephone follow-up was 
performed at 30 days in order to assess mortality. 
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At the end of the study period, two expert emergency physicians (LMC and GCA) evaluated the 
clinical record of each patient in order to assess the final diagnosis according to the Sepsis-3 criteria. 
Therefore, patients were firstly divided in two groups depending on whether the suspected sepsis 
detected at ED admission was later confirmed (“sepsis”) or ruled out (“non-sepsis”). Then, septic 
patients were further divided in two groups (notably “sepsis” and “septic shock”) in order to perform 
additional analyses. 
2.2. Experimental Analysis 
OPN plasma levels were determined at the end of the study period in the stored samples 
collected at the time of enrollment. Circulating OPN was quantified using commercially available 
ELISA (enzyme-linked immunosorbent assay; R&D system codes DY1433 and DY007) according to 
the manufacturer’s protocol. The optimal sample dilution was set at 1:1000 and the measure unit was 
ng/mL. 
OPN levels were determined in 10 healthy subjects with similar age and gender distributions as 
those in the study group in order to have a control group. 
2.3. Statistical Analysis 
Statistical analysis was performed with the MedCalc® software v12.5.0 (MedCalc software bvba, 
Ostend, Belgium). Continuous variables were analyzed through the Mann–Whitney U test and 
logistic regressions were then used to identify independent predictors of sepsis. The Chi-square test 
was used to analyze categorical variables.  
The area under the Receiver Operating Characteristic (ROC) curve for the ability of OPN to 
distinguish septic patients from the non-septic ones and its best cut-off were calculated. 
Subsequently, we performed a pairwise comparison of the ROC curve for OPN and for the variables 
that were significantly different between the sepsis and non-sepsis groups, using the DeLong method 
with the Bonferroni correction. 
In order to exclude the presence of potential confounders, the relationships between OPN levels 
and a few relevant variables were analyzed in the overall population using the Mann–Whitney U test 
(for categorical variables) or the rank correlation (for continuous variables). A multiple regression 
analysis was then performed to identify independent predictors of OPN concentration. 
Survival times were calculated starting from the time of patients’ enrollment: the log-rank test 
was used to identify groups with different survival probabilities, graphically presented in Kaplan–
Meier plots; hazard ratios (HR) and 95% confidence intervals (CI) were also calculated. Eventually, a 
Cox proportional hazard model was built to analyze the weight of mortality predictors identified at 
univariate analysis. 
Statistical significance was set at two-tailed p < 0.05. 
3. Results 
From October 2016 to March 2018, 102 consecutive patients with suspected sepsis were enrolled 
in this study. One of them retired his consent soon after enrollment; the final analysis therefore 
included 101 patients. 
The main characteristics of the overall population are reported in Table 1. 
Table 1. Main general, clinical and laboratory data of the study population. Data are presented for 
the whole population in the second column. The last three columns represent the data of patients with 
or without sepsis and their statistical comparison. Continuous variables are presented as medians and 
interquartile ranges; categorical variables are presented as frequencies (%). 
 
All patients (N. 101) Non-sepsis (N. 9) Sepsis (N. 92) p-value 
General characteristics 
Age, years 80 (73–88) 84 (64–90) 80 (73–88) 0.934 
Sex, M / F 57 (56.4%) / 44 (43.6%) 7 (77.8%) / 2 (22.2%) 50 (54.3%) / 42 (45.7%) 0.317 
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BMI, kg/m2 24.8 (22.0–27.5) 28.9 (24.6–31.2) 24.2 (22.0–27.1) 0.071 
Comorbidities 
Heart failure 25 (24.8%) 3 (33.3%) 22 (24.0%) 0.826 
Previous stroke 19 (18.8%) 1 (11.1%) 18 (19.6%) 0.863 
Dementia 28 (27.7%) 2 (22.2%) 26 (28.3%) 0.997 
COPD 17 (16.8%) 1 (11.1%) 16 (17.4%) 0.989 
Diabetes mellitus 33 (32.7%) 1 (11.1%) 32 (34.8%) 0.283 
Neoplasia 24 (23.8%) 1 (11.1%) 23 (25.0%) 0.600 
Arterial 
hypertension 
71 (70.3%) 7 (77.8%) 64 (69.6%) 0.895 
CKD 31 (30.7%) 3 (33.3%) 28 (30.4%) 0.948 
Initiated antibiotic 
treatment ‡ 
22 (21.8%) 1 (11.1%) 21 (22.8%) 0.674 
Clinical parameters 
HR, bpm 107 (91–125) 80 (73–108) 110 (93–126) 0.029 * 
MAP, mmHg 73.3 (64.6–95.0) 76.3 (70.0–103.9) 73.3 (61.7–94.2) 0.270 
RR, breaths per 
minute 
30 (25–36) 26 (24–30) 30 (26–36) 0.056 
POS, % 91 (85–95) 96 (94–98) 90 (85–95) 0.009 * 
GCS 13 (11–14) 13 (12–14) 13 (10–14) 0.316 
Body temperature, 
°C 
37.9 (37.3–38.8) 37.7 (36.0–38.5) 38.0 (37.3–38.8) 0.459 
Laboratory data 
WBCs, ×103/mm3 14.44 (9.46–20.40) 12.99 (10.00–16.56) 14.57 (9.26–21.78) 0.520 
Hb, g/dL 12.3 (10.8–13.6) 12.1 (11.5–14.3) 12.4 (10.8–13.5) 0.962 
PLTs, ×103/mm3 217 (160–295) 206 (177–301) 218 (149–294) 0.757 
Glucose, mg/dL 138 (104–191) 136 (122–148) 139 (103–217) 0.807 
Creatinine, mg/dL 1.45 (0.94–2.12) 1.18 (0.88–1.66) 1.54 (0.94–2.15) 0.311 
Total bilirubin, 
mg/dL 
0.7 (0.5–1.3) 0.5 (0.5–1.0) 0.8 (0.5–1.4) 0.197 
CRP, mg/dL 12.77 (3.12–19.40) 2.10 (1.40–14.67) 13.24 (3.40–19.57) 0.127 
Arterial pH 7.44 (7.39–7.48) 7.44 (7.37–7.48) 7.44 (7.39–7.48) 0.826 
Plasma lactate, 
mmol/L 
2.5 (1.6–4.8) 0.8 (0.7–1.6) 2.8 (1.8–5.3) <0.001 * 
PaO2/FiO2, mmHg 250.0 (210.2–321.6) 300.5 (225.2–358.0) 247.6 (210.0–313.4) 0.255 
OPN, ng/mL 204.6 (112.5–376.8) 91.3 (63.9–105.4) 225.2 (138.2–387.8) <0.001 * 
Scores 
qSOFA, 2 / 3 † 69 (68.3%) / 32 (31.7%) 7 (77.8%) / 2 (22.2%) 62 (67.4%) / 30 (32.6%) 0.792 
SOFA 6 (4–7) 4 (2–5) 6 (4–7) 0.021 * 
* and bold value indicate statistical significance according to P-value < 0.05. ‡ patients were included 
in this group if antibiotic treatment had been already initiated before ED admission. † patients were 
divided according to the qSOFA score in two groups (qSOFA = 2 vs. qSOFA = 3).  
Abbreviations list: BMI: body mass index; COPD: chronic obstructive pulmonary disease; CKD: 
chronic kidney disease; HR: heart rate; MAP: mean arterial pressure; RR: respiratory rate; POS: 
peripheral oxygen saturation; GCS: Glasgow Coma Scale; WBCs: white blood cells, Hb: haemoglobin; 
PLTs: platelets; CRP: C-reactive protein; PaO2/FiO2: ratio between partial pressure of oxygen and 
fractional inspired oxygen; OPN: plasma Osteopontin concentration; SOFA: Sepsis-related Organ 
Failure Assessment; qSOFA: quick SOFA. 
In 9 out of 101 patients (8.9%) sepsis was eventually ruled out, with the alternative definitive 
diagnosis being either non-infectious conditions (66.7%) or infections without organ dysfunction 
(33.3%): specifically, these alternative diagnosis were acute heart failure (33.3%), pulmonary 
embolism (22.2%), uncomplicated urinary tract infection (22.2%), ischemic bowel disease (11.1%) and 
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dehydration due to acute diarrhea without sepsis (11.1%). Among the remaining 92 subjects (91.1%), 
68 were diagnosed with sepsis (73.9%) and 24 with septic shock (26.1%). 
3.1. Diagnosis 
The comparison between septic (including both sepsis and septic shock) and non-septic patients 
showed significant differences in terms of SOFA score (6 vs 4, p = 0.021), heart rate (110 vs 80 bpm, P 
= 0.029), peripheral oxygen saturation (90% vs. 96%, p = 0.009) and plasma lactate concentration (2.8 
vs. 0.8 mmol/L, p < 0.001). Body mass index (BMI) and respiratory rate (RR) were different at a non-
significant level. Plasma OPN levels were found to be significantly higher in patients with sepsis 
(225.2 vs 91.3 ng/mL, p < 0.001) (see again Table 1 for all variables details).  
A logistic regression analysis including all the above-mentioned variables together with age 
showed that OPN was an independent predictor of sepsis (OR = 1.020, 95% CI 1.002 to 1.039 with p = 
0.031). Moreover, higher BMIs reduced the probability that the patients actually had sepsis (OR = 
0.656, 95% CI 0.455 to 0.947 with p = 0.024). None of the other included variables was an independent 
predictor of sepsis according to this model (Table 2). 
Table 2. Logistic regression model of the predictors of sepsis. The Table shows the OR resulted from 
multivariate analysis. Variables were selected if their P-values at univariate analysis were < 0.10 (see 
Table 1). 
 OR 95% CI P-value 
Age  0.976 0.876–1.087 0.656 
BMI 0.656 0.455–0.947 0.024 * 
HR 1.003 0.937–1.074 0.934 
RR 1.187 0.896–1.574 0.233 
POS 1.008 0.808–1.256 0.946 
Plasma lactate 4.546 0.500–41.303 0.179 
OPN 1.020 1.002–1.039 0.031 * 
SOFA 1.799 0.840–3.849 0.131 
* and bold value indicate statistical significance according to p-value < 0.05. 
Abbreviations list: OR: odds ratio; CI: confidence interval; BMI: body mass index; HR: heart rate; RR: 
respiratory rate; POS: peripheral oxygen saturation; OPN: plasma Osteopontin concentration; SOFA: 
Sepsis-related Organ Failure Assessment score. 
The diagnostic performance of OPN was also evaluated through a ROC curve analysis (Figure 
1). The area under the curve (AUC) was 0.878 (95% CI 0.798 to 0.935) and a cut-off of 112.8 ng/mL 
showed an 80.4% sensitivity and an 88.9% specificity in detecting septic patients (Youden’s index J = 
0.693). The comparison between the ROC curve for OPN and those for heart rate, peripheral oxygen 
saturation, plasma lactate and SOFA score, showed no significant differences, being OPN AUC nearly 
identical to the plasma lactate one (0.877, 95% CI 0.796 to 0.934). 
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Figure 1. This figure represents the diagnostic performance of OPN in discriminating non-septic from 
septic patients. Receiving Operating Characteristic (ROC) curve analysis with area under the curve 
(AUC) was performed and reported in the figure. 
OPN levels were found to be slightly higher in patients with septic shock compared to those 
with sepsis, although this difference was not statistically significant (243.3 ng/mL vs 211.6 ng/mL, P 
= 0.138). Circulating OPN was significantly lower in healthy controls compared to all the enrolled 
patients (35.2 vs 204.6 ng/mL, p < 0.0001). 
3.2. Independent Predictors of OPN Concentration 
In order to identify the variables that could affect OPN circulating levels and act as potential 
confounders, the Mann–Whitney U test was used to compare OPN between males and females and 
between patients with or without certain comorbidities, while the rank correlation test was used to 
explore the association between OPN levels and a few relevant continuous variables (age, SOFA 
score, laboratory parameters). This analysis (reported in detail in Table 3) showed that, among the 
investigated variables, only plasma lactate ( = 0.370 with p = 0.0001), plasma creatinine ( = 0.262 
with p = 0.008) and SOFA score ( = 0.243 with p = 0.014) were positively correlated to OPN. 
Table 3. Univariate analysis of potential predictors of OPN levels. Patients were divided into two 
groups according to sex and to the presence or absence of certain comorbidities and the Mann–
Whitney U test was used to compare OPN between them (the first column reports median and 
interquartile range of OPN concentration in the groups). The rank correlation was used to investigate 
the relationship between OPN levels and a few relevant continuous variables (the second column 
reports the Spearman’s , while the third reports the 95% CI). The forth column reports the p-value 
for each test. 
 OPN, ng/mL  95% CI p-value 
Categorical variables     
Sex 
M 191.3 (105.7–353.7)   
0.511 
F 226.0 (123.0–387.8)   
Heart failure Y 190.0 (107.3–237.8)   0.325 
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N 225.2 (117.3–387.8)   
Previous stroke 
Y 226.1 (115.0–355.6)   
0.768 
N 193.6 (112.8–378.8)   
Dementia 
Y 228.0 (149.0–354.6)   
0.750 
N 193.1 (106.1–386.7)   
COPD 
Y 215.4 (107.5–390.5)   
0.806 
N 193.6 (117.1–377.5)   
Diabetes mellitus 
Y 204.6 (125.6–380.5)   
0.789 
N 200.2 (112.2–354.6)   
Neoplasia 
Y 225.3 (165.3–411.0)   
0.128 
N 190.0 (107.7–350.8)   
Arterial hypertension 
Y 206.3 (122.8–384.0)   
0.542 
N 192.0 (99.1–345.9)   
CKD 
Y 189.9 (108.8–344.1)   
0.581 
N 207.0 (122.6–385.7)   
Continuous variables     
SOFA  0.243 0.050–0.418 0.014 * 
Age, years  0.112 −0.085–0.301 0.264 
BMI, kg/m2  −0.038 −0.233–0.161 0.711 
Creatinine, mg/dL  0.262 0.070–0.435 0.008 * 
PaO2/FiO2, mmHg  −0.139 −0.326–0.058 0.165 
WBCs, ×103/mm3  0.070 −0.128–0.262 0.489 
PLTs, ×103/mm3  0.003 −0.192–0.198 0.975 
CRP, mg/dL  0.161 −0.036–0.345 0.108 
Arterial pH  −0.114 −0.303–0.083 0.257 
Plasma lactate, mmol/L  0.370 0.188–0.527 0.0001 * 
* and bold value indicate statistical significance according to P-value < 0.05. 
Abbreviations list: OPN: plasma Osteopontin concentration; COPD: chronic obstructive pulmonary 
disease; CKD: chronic kidney disease; SOFA: Sepsis-related Organ Failure Assessment; BMI: body 
mass index; PaO2/FiO2: ratio between partial pressure of oxygen and fractional inspired oxygen; 
WBCs: white blood cells; PLTs: platelets; CRP: C-reactive protein. 
However, when the three variables were included into a multiple regression analysis, only the 
increase in plasma creatinine turned out to be significantly associated to an increase in plasma OPN 
(r = 0.401 with p = 0.0001). 
As reported in Table 1, no difference was found in creatinine levels between septic and non-
septic patients (p = 0.311). Therefore, data obtained from septic patients were retrospectively 
reviewed in order to identify those who met the KDIGO (Kidney Disease Improving Global 
Outcome) criteria for acute kidney injury (AKI) [18]. Forty-seven out of 92 patients (51.1%) met the 
diagnostic criteria for AKI, but no significant difference emerged in OPN concentration between AKI 
and non-AKI patients (233.3 vs 190.0 ng/mL, p = 0.119). 
3.3. Mortality 
Mortality rates at 30 days were evaluated dividing patients in three groups: non-sepsis, sepsis 
and septic shock. We observed a significant difference in mortality rates, which were progressively 
higher in non-septic, septic and septic shock patients (11.1% vs 27.9% vs 62.5%, respectively, p = 0.003) 
(Table 4). 
Table 4. This table represents mortality rates at 30 days according to the different diagnosis groups. 
 Non-sepsis (N. 9) Sepsis (N. 92) p-value 
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30-days mortality 1/9 (11.1%) 34/92 (37.0%) 0.235 
 Non-sepsis (N. 9) Sepsis (N. 68) Septic shock (N. 24) p-value 
30-days mortality 1/9 (11.1%) 19/68 (27.9%) 15/24 (62.5%) 0.003 * 
* and bold value indicate statistical significance according to p-value < 0.05 for Chi-square test. 
Figure 2 reports the Kaplan–Meier curves that represent survival rates for the follow-up period 
of 30 days. Statistical significance was reached both when all three diagnosis were considered (p < 
0.001) and when only sepsis and septic shock were compared (p < 0.001). 
 
Figure 2. This figure shows the survival rates of the three diagnosis groups during the follow-up 
period of 30 days. Below the plot there is the “number at risk” table, indicating the number of patients 
alive in each group at every major timepoint. 
Considering only septic patients (including both sepsis and septic shock), GCS, CRP, arterial 
blood pH, plasma lactate, the PaO2/FiO2 ratio, qSOFA and SOFA turned out to be significantly 
different between alive and dead patients at 30 days; OPN concentration was not different between 
the two groups (231.3 ng/mL in dead patients vs. 216.8 ng/mL in alive patients, p = 0.482) (Table 5). 
Table 5. Main general, clinical and laboratory data of the 92 patients with sepsis divided according to 
being alive or dead at 30 days. Continuous variables are presented as medians and interquartile range; 
categorical variables are presented as frequencies (%). 
 Alive at 30 days (N. 58) Dead at 30 days (N. 34) p-value 
General characteristics 
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Age, years 80 (71–86) 84 (75–89) 0.175 
Sex, M / F 33 (56.8%) / 25 (43.2%) 17 (50.0%) / 17 (50.0%) 0.671 
BMI, kg/m2 25.0 (22.2–27.3) 24.1 (21.3–26.1) 0.283 
Comorbidities 
Heart failure 14 (24.1%) 8 (23.5%) 0.852 
Previous stroke 8 (13.8%) 10 (29.4%) 0.121 
Dementia 17 (29.3%) 9 (26.5%) 0.958 
COPD 11 (19.0%) 5 (14.7%) 0.814 
Diabetes mellitus 20 (34.5%) 12 (35.3%) 0.882 
Neoplasia 15 (25.8%) 8 (23.5%) 0.999 
Arterial hypertension 42 (72.4%) 22 (64.7%) 0.589 
CKD 17 (29.3%) 11 (32.4%) 0.880 
Initiated antibiotic treatment ‡ 14 (24.1%) 7 (20.6%) 0.824 
Clinical parameters 
HR, bpm 107 (92–125) 113 (94–127) 0.710 
MAP, mmHg 73.3 (61.7–95.0) 73.3 (61.7–93.3) 0.900 
RR, breaths per minute 28 (25–35) 32 (26–40) 0.080 
POS, % 91 (86–95) 89 (81–94) 0.122 
GCS 13 (11–14) 12 (9–13) 0.010 * 
Body temperature, °C 38.0 (37.3–38.9) 37.8 (37.2–38.7) 0.201 
Laboratory data 
WBCs, ×103/mm3 13.87 (8.30–20.86) 15.09 (9.80–24.16) 0.656 
Hb, g/dL 12.3 (10.9–13.5) 12.6 (10.5–13.5) 0.815 
PLTs, ×103/mm3 218 (163–294) 216 (128–290) 0.680 
Glucose, mg/dL 142 (108–190) 131 (90–224) 0.332 
Creatinine, mg/dL 1.39 (0.94–2.09) 1.66 (1.08–2.39) 0.280 
Total bilirubin, mg/dL 0.7 (0.6–1.4) 0.8 (0.3–1.4) 0.491 
CRP, mg/dL 10.36 (2.92–17.20) 15.72 (6.21–19.94) 0.046 * 
Arterial pH 7.44 (7.42–7.49) 7.40 (7.36–7.46) 0.012 * 
Plasma lactate, mmol/L 2.4 (1.6–4.0) 3.2 (2.1–6.8) 0.029 * 
PaO2/FiO2, mmHg 260.0 (230.0–336.7) 234.5 (182.2–259.5) 0.023 * 
OPN, ng/mL 216.8 (144.0–356.6) 231.3 (123.4–526.4) 0.482 
Scores 
qSOFA, 2 / 3 † 44 (75.9%) / 14 (24.1%) 18 (52.9%) / 16 (47.1%) 0.042 * 
SOFA 5 (4–7) 7 (5–8) 0.023 * 
* and bold value indicate statistical significance according to P-value < 0.05. ‡ patients were included 
in this group if antibiotic treatment had been already initiated before ED admission. † patients were 
divided according to the qSOFA score in two groups (qSOFA = 2 vs. qSOFA = 3).  
Abbreviations list. BMI: body mass index; COPD: chronic obstructive pulmonary disease; CKD: 
chronic kidney disease; HR: heart rate; MAP: mean arterial pressure; RR: respiratory rate; POS: 
peripheral oxygen saturation; GCS: Glasgow Coma Scale; WBCs: white blood cells, Hb: haemoglobin; 
PLTs platelets; CRP: C-reactive protein; PaO2/FiO2: ratio between partial pressure of oxygen and 
fractional inspired oxygen; OPN: plasma Osteopontin concentration; SOFA: Sepsis-related Organ 
Failure Assessment; qSOFA: quick SOFA. 
The Cox proportional hazard model built on the basis of this univariate analysis did not include 
OPN and is therefore provided in the Supplementary Material. 
The same analysis was performed considering 7-days mortality, but once again OPN showed a 
poor prognostic performance and was not identified as an independent predictor of worse outcome 
(data available in the Supplementary Material). 
4. Discussion 
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In this pilot study, performed on a cohort of 101 patients admitted to the ED over an 18-month 
period, we show that the baseline value of plasmatic OPN is a promising diagnostic biomarker for 
the early diagnosis of sepsis. Nevertheless, OPN did not act as a prognostic tool. 
Although OPN levels have been previously studied in sepsis, our findings bring some elements 
of innovation. First of all, the role of OPN as a diagnostic biomarker had never been specifically 
investigated in the first approach to patients with suspected sepsis in an ED setting. Secondly, to our 
best knowledge this is the first study in which both the enrollment and the diagnostic classification 
of patients were performed according to the new definitions of sepsis and septic shock. 
Among the 101 patients enrolled in the study, 92 of them showed a combination of infection and 
organ dysfunction, whereas nine had conditions that mimicked sepsis (including both non-infectious 
organ dysfunctions and uncomplicated infections). The comparison of these two groups revealed that 
OPN was significantly higher in septic patients. 
Compared to the plasmatic levels reported in other studies, we observed lower OPN values 
[15,17]: on the one hand this could be explained by the different setting in which we performed the 
study (ED vs ICU). On the other hand, the difference could be explained by the fact that we 
determined OPN levels at presentation, when the biohumoral modifications of sepsis are still 
developing. 
Interestingly, OPN levels progressively increased throughout healthy controls, non-infectious 
conditions, sepsis and septic shock. This is coherent with the results of other studies [15] and proves 
that a pro-inflammatory state is present also in non-septic conditions and that OPN is involved in the 
pathogenesis of these inflammatory processes, since higher levels correspond to clinical syndromes 
with a more pronounced inflammatory dysregulation. 
The correlation observed between OPN and creatinine plasma levels is in line with data from 
previous studies [19]. However, our hypothesis that this finding may be explained by a high rate of 
AKI in septic patients was not supported by the results: in fact, although OPN has been already 
described as a biomarker of AKI in critically ill patients [20], OPN levels did not differ significantly 
between AKI and non-AKI patients. Our data do not allow us to discriminate among a mere retentive 
effect caused by renal failure, an increase due to an active OPN secretion in an inflammatory setting 
or the coexistence of both these mechanisms which eventually lead to a vicious circle of accumulation 
and renal damage. However, further studies would be needed to deepen this issue and produce more 
conclusive results. 
This biomarker resulted to be an independent diagnostic predictor of sepsis and showed a good 
diagnostic performance at the ROC curve analysis, where the highest sensitivity (88.9%) and 
specificity (80.4%) were seen when the cut-off was set at 112.8 ng/mL. However, when the ROC curve 
for OPN was compared to those for other potential markers of sepsis identified at univariate analysis 
(heart rate, peripheral oxygen saturation, plasma lactate and SOFA score), no significant difference 
was found. In particular, the AUC for OPN was very similar to the one for plasma lactate, a parameter 
widely and routinely used in the diagnostic workup and prognostic stratification of sepsis [21]. These 
data suggest that a single determination of plasma OPN in patients presenting with a suspected 
infection and a qSOFA score ≥ 2 can strengthen the suspicion of sepsis. 
According to the design of this exploratory study, we did not enroll septic patients with qSOFA 
≤ 1, which could have allowed us to evaluate the ability of OPN to increase the qSOFA sensitivity. 
However, the diagnostic value of OPN could be further tested in studies aimed at demonstrating 
whether it could increase the sensitivity of currently available clinical scores. In this context, by 
reinforcing the association between OPN and sepsis, our study opens new highly relevant scenarios. 
In fact, OPN targeting might be considered a potential promising therapeutic strategy in septic 
patients. This is in line with previous reports, according to which OPN might play an important 
pathophysiologic role in the development of the systemic inflammation and the subsequent organ 
injury that characterizes sepsis. In a murine model of sepsis with acute lung injury (ALI), the 
neutralization of OPN with specific antibodies significantly reduced the circulating levels of pro-
inflammatory cytokines, their mRNA expression in the lungs and even the levels of some biomarkers 
of organ injury [22]. 
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Mortality rates at 30 days were not different between septic and non-septic patients. However, 
when the sepsis group was further divided in sepsis and septic shock, the comparison reached 
statistical significance as mortality rates were found to increase according to the severity of the 
disease. This latter observation was confirmed by the Kaplan–Meier curves reported in Figure 2. 
The mortality rates observed in septic patients (including both sepsis and septic shock) were in 
line with those usually described in the literature. Nonetheless, mortality rates in septic shock alone 
were found to be higher than those reported in other studies [1]. This could be explained both by the 
characteristics of our population and by the study design itself. On the one hand, enrolled patients 
were mostly elderly affected by multiple comorbidities. On the other hand, the protocol of the study 
did not specifically exclude patients who had no indication to resuscitating procedures or intensive 
treatments because of their general condition, age and comorbidities, whereas many studies reported 
in the literature are designed to exclude “do not resuscitate” (DNR) patients (an international legal 
definition which has no equivalents in the Italian Law). This may have contributed to increase 
mortality rates in the septic shock group, since we retrospectively identified five patients (20.8% of 
all septic shock patients and 41.7% of the deaths observed within the first few days from admission) 
in which intensive treatments (such as admission to ICU, invasive monitoring, amine treatment and 
intensive resuscitation) were considered to be a form of futile medical care by the treating physicians. 
The survival analysis showed that circulating OPN was not an independent predictor of 
mortality in our cohort of patients with sepsis. Actually, no significant difference was found in OPN 
levels between dead and alive patients at 30 days. This is not consistent with the data reported in the 
literature that, instead, attribute to OPN a good prognostic performance [17]. This may be explained 
by the timing of the determination of OPN levels in this study: subsequent measurements may have 
detected a difference that was not evident at the time of presentation. Therefore, the lack of further 
determination of OPN levels is another limitation of this study. In particular, having more 
information about the OPN time course might have allowed us to detect the peak of OPN 
concentration, known to be associated with increased mortality [15]. On the basis of our results we 
can only state that a single early OPN determination cannot be used as a prognostic tool. Eventually, 
another limitation of this pilot study is the small number of non-septic patients. However, due to the 
study design itself, the composition of the two groups remained unknown until the end of the study 
period, when the diagnostic workup of all the enrolled patients was completed. The inclusion criteria, 
as expected, allowed us to identify patients with sepsis with a good accuracy: the ratio between no 
sepsis and sepsis patients in our cohort was 1:10. In this regards, our results are in line with the 
findings of previously published studies [23]. 
5. Conclusions 
A single determination of OPN at presentation can help to identify patients with sepsis in the 
ED, since its circulating levels are higher in sepsis compared to different acute conditions that can 
mimic sepsis. OPN concentration tends to increase according to the severity of the disease, being the 
highest in septic shock. Nevertheless, a single determination of OPN was not able to predict poor 
prognosis in this cohort of septic patients. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1. Supplementary 
Materials provide further data about the analysis of the prognostic role of OPN in sepsis. 
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